Cellectis

Source: Wikipedia, the free encyclopedia.

Cellectis
Websitecellectis.com

Cellectis is a French

T-cell technologies for cancer immunotherapy.[1] It has offices in Paris, New York City, and Raleigh, North Carolina
.

History

Cellectis was founded by

stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology,[3] and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company.[2] In January 2011 the company licensed TALEN gene-editing technology from Iowa State University and the University of Minnesota.[4][5] The company employed nearly 300 people in early 2014.[2]

With the advent of the CRISPR (

CAR-T technologies for cancer immunotherapy. Early in 2014 it reached a substantial financing deal with Servier, and later in the same year made a much larger agreement with Pfizer and Allogene.[2]

In March 2015 the company raised $228 million through a stock offering on

NASDAQ. The shares fell by 15% in the first week of trading.[6]

Cellectis has two manufacturing facilities - one in

Paris, France, and one in Raleigh, North Carolina.[7]

Calyxt

Cellectis formed the subsidiary of Calyxt in 2010[8] to develop healthier food ingredients through gene editing.[9] Based in Roseville, Minnesota, the subsidiary filed for an IPO in June, 2017.[10]

CAR-T cancer treatment

Cellectis has developed

graft vs host disease). The base cells can then be modified the same way other CAR-T therapeutics are.[12]

In 2017, UCART123 was in phase 1 trials for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukaemia (AML).[13] In early September 2017, the FDA suspended Cellectis’ Phase I trials of UCART123 in the wake of the death of a BPDCN patient from cytokine release syndrome (CRS).[13] The FDA hold was lifted in November 2017 after reducing the dosage and with additional conditions.[14] Cellectis also has a phase 1 trial for UCART22 in B-cell acute lymphoblastic leukemia (B-ALL) and received an IND approval from the FDA on their UCARTCS1 product candidate in multiple myeloma.[15]

References

  1. ^ "Biotech Cellectis in takeover talks with Pfizer". Financial Times. 28 May 2015. Retrieved 2 March 2023.
  2. ^ a b c d Philip Hemme (15 July 2015). "How Servier saved Cellectis, the French CAR-T Miracle". Labiotech.eu. Retrieved 16 March 2016.
  3. ^ "Genetic Engineering & Biotechnology News - Biotech from Bench to Business". Genengnews.com. 8 November 2013. Archived from the original on 22 March 2016. Retrieved 16 March 2016.
  4. S2CID 20875262
    .
  5. ^ "Cellectis Nabs TAL Effector IP from Minnesota and Iowa State Universities". GEN. 20 January 2011.
  6. ^ "US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat". NASDAQ.com. 27 March 2015. Retrieved 18 September 2017.
  7. ^ "Cellectis to bring CAR-T manufacturing in-house with new plants". BioPharma Dive. Retrieved 11 July 2019.
  8. ^ Rehkamp, Patrick (21 July 2017). "Biotech firm Calyxt goes public, shares climb 30 percent". www.bizjournals.com. Retrieved 8 October 2017.
  9. ^ "The First Gene-Edited Food Is Now Being Served". Twin Cities Business. Retrieved 18 January 2018.
  10. ^ "Agricultural biotechnology company Calyxt files for IPO". Star Tribune. Retrieved 26 October 2017.
  11. ^ Weintraub, Karen. "Powerful Childhood Cancer Treatment Holds Promise--and Poses Hazards". Scientific American. Retrieved 8 October 2017.
  12. ^ "Gene editing has saved the lives of two children with leukaemia". New Scientist. Retrieved 8 October 2017.
  13. ^ a b McKee, Selina (5 September 2017). "FDA holds trials of Cellectis' cell therapy after patient death". www.pharmatimes.com. Retrieved 8 October 2017.
  14. ^ FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN. nov 2017
  15. ^ "Possible Multiple Myeloma CAR T-cell Therapy to Enter Phase 1 Trial, Cellectis Says". Myeloma Research News. 22 April 2019. Retrieved 11 July 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cellectis&oldid=1178544403"